Zydus Lifesciences Limited has informed the Exchange regarding a press release dated February 06, 2026, titled "Zydus receives USFDA Orphan Drug Designation (ODD) for Desidustat for the treatment of Sickle Cell Disease".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has received USFDA Orphan Drug Designation (ODD) for its drug Desidustat for the treatment of Sickle Cell Disease. Orphan Drug Designation is granted to drugs intended to treat rare diseases, and it typically provides benefits such as 7 years of market exclusivity upon approval, fee waivers, and tax credits. Sickle Cell Disease is a rare genetic blood disorder, and this designation represents a significant regulatory milestone for Zydus. The press release was dated February 6, 2026.
This is a positive development that strengthens Zydus's pipeline in a rare disease segment and could enhance the commercial value of Desidustat in the US market. It may boost investor sentiment, though material revenue impact would depend on eventual approval and launch.